The results supported the hypothesis that TG02 may target both of the key elements of the pathogenesis of CLL: the deregulated BCR signaling in the lymphoid tissue and the overexpression of the anti-apoptotic proteins that sustain CLL cell viability. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.